报告题目：Development and clinical translation of target-directed anti-cancer drugs（抗肿瘤标靶药物的开发与临床转译）
报告人： 陈庆士(Ching-Shih Chen)博士，俄亥俄州立大学药学院教授
报告地点：独墅湖校区二期云轩楼1319室
报告时间：2009年10月20日星期二 下午2:00
欢迎师生参加！
医学部药学院
2009年10月15日
陈庆士教授介绍：
OSU College of Pharmacy
Professor of Medicinal Chemistry, Internal Medicine, and Urology
Lucius A. Wing Chair of Cancer Research & Therapy; Kimberly Professor
A. Education, Positions and Honors
Education:
INSTITUTION AND LOCATION | DEGREE (if applicable) | YEAR(s) | FIELD OF STUDY |
National Taiwan University | B.S. | 1978 | Agri. Chemistry |
National Taiwan University | M.S. | 1980 | Biochemistry |
University of Wisconsin - Madison | Ph.D. | 1985 | Pharm. Biochemistry |
University of Wisconsin - Madison | PostDoc | 1986 | Med. Chemistry |
Positions:
1987-1991 Assistant Professor of Medicinal Chemistry & Pharmacognosy, University of Rhode Island
1991-1995 Associate Professor of Medicinal Chemistry & Pharmacognosy, University of Rhode Island
1995-1998 Associate Professor of Pharmaceutical Sciences, University of Kentucky
1995-2001 Member, Markey Cancer Center, University of Kentucky
1998-2001 Professor of Pharmaceutical Sciences, University of Kentucky
2001-present Professor of Medicinal Chemistry, The Ohio State University
2001-present Member, James Comprehensive Cancer Center, The Ohio State University
2002-present Professor of Internal Medicine and Urology, The Ohio State University
Honors (in the past five years)
2003 - 2006 Kimberly Chair Professorship, OSU College of Pharmacy
2004 - present Elected Fellow, American Association for the Advancement of Science (AAAS)
2004 Winner of the V Foundation-AACR Grants in Translational Cancer Research
2005 - present Advisory Board Committee, Institute of Biological Chemistry, Academia Sinica, Taiwan; National Science and Technology Program in Biotechnology and Pharmaceuticals, Taiwan
2005 - present The Lucius A. Wing Chair of Cancer Research and Therapy, OSU Comprehensive Cancer Center
2005 - 2009 Chartered member, Basic Mechanism for Cancer Therapeutics (BMCT) Study Section, NCI
2008 Innovation in Drug Discovery Award, College of Pharmacy, The Ohio State University
B. Areas of Interest
Dr. Chen’s research focuses on exploring signaling pathways that govern cancer cell survival as targets for drug discovery and design. He employs a multidisciplinary approach to identify new molecular targets by combining expertise ranging from synthetic organic chemistry to molecular and cellular biology in his research team. His laboratory has designed a series of novel small-molecule agents that cause apoptosis by attacking different molecular defects in tumor cells. These molecular targets include Akt signaling, Bcl-xL/Bcl-2, histone deacetylase, DNA methyltransferase, cyclin D1, b-catenin, and androgen receptor. These novel agents mediate antiproliferative effects through mechanisms distinct from that of conventional chemotherapeutic regimens, which will provide a rational approach for molecular targeted cancer therapy. Currently, many of these promising compounds are undergoing in vivo target validation in his laboratory using a number of cancer models including prostate, breast, lung, liver, and ovarian cancers. Two of these agents, the PDK-1 inhibitor OSU-03012 and the histone deacetylase inhibitor HDAC-42, are currently undergoing preclinical testing under the Rapid Access to Intervention Development (RAID) program at the National Cancer Institute, which will facilitate the translation of these agents into the clinic.
(药学院)
